NCT06904196 2025-04-29
Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC
Second Affiliated Hospital of Guangzhou Medical University
Phase 2 Recruiting
Clinical Trials
4 trialsNCT06447727 2024-06-07
Efficacy and Safety of 90Y Microsphere Combined With FOLFIRI and Bevacizumab in Second-line Treatment of CRLM
Zhongda Hospital
Recruiting
NCT05992584 2023-09-14
Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC
Second Affiliated Hospital of Guangzhou Medical University
Phase 2 Recruiting
NCT05994859 2023-09-14
SIRT for Potentially Resectable HCC
Second Affiliated Hospital of Guangzhou Medical University
Phase NA Recruiting